UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 183

Sortiert nach

Top advances of the year: Breast cancer

Cancer, 2023-06, Vol.129 (12), p.1791-1794

2023

Volltextzugriff (PDF)

Enhancing global access to cancer medicines

CA: a cancer journal for clinicians, 2020-03, Vol.70 (2), p.105-124

2020

Volltextzugriff (PDF)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Nature communications, 2020-01, Vol.11 (1), p.385-385, Article 385

2020

Volltextzugriff (PDF)

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2474-2481

2009

Volltextzugriff (PDF)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Therapeutic Advances in Medical Oncology, 2021-11, Vol.13, p.17588359211059587

2021

Volltextzugriff (PDF)

CDK4/6 inhibitors in breast cancer: spotting the difference

Nature medicine, 2021-11, Vol.27 (11), p.1868

2021

Volltextzugriff (PDF)

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3781-3787

2015

Volltextzugriff (PDF)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

NPJ breast cancer, 2021-11, Vol.7 (1), p.145-145, Article 145

2021

Volltextzugriff (PDF)

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

Clinical cancer research, 2005-12, Vol.11 (24), p.8715-8721

2005

Volltextzugriff (PDF)

Nobody dares stopping clinical research, not even COVID-19

NPJ breast cancer, 2021-04, Vol.7 (1), p.39-39, Article 39

2021

Volltextzugriff (PDF)

Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality

PloS one, 2021-08, Vol.16 (8), p.e0256205-e0256205

2021

Volltextzugriff (PDF)

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4530-4535

2009

Volltextzugriff (PDF)

Anti-Anisakis antibodies in colon cancer patients and their relationship with γδ T-cells

Parasitology research (1987), 2024-04, Vol.123 (4), p.196-196, Article 196

2024

Volltextzugriff (PDF)

The role of CDK4/6 inhibitors in early breast cancer

Breast (Edinburgh), 2021-08, Vol.58, p.160-169

2021

Volltextzugriff (PDF)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.133-133, Article 133

2019

Volltextzugriff (PDF)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Cancers, 2021-08, Vol.13 (17), p.4280

2021

Volltextzugriff (PDF)

Differences in circulating γδ T cells in patients with primary colon cancer and relation with prognostic factors

PloS one, 2020-12, Vol.15 (12), p.e0243545

2020

Volltextzugriff (PDF)

ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Clinical cancer research, 2018-06, Vol.24 (11), p.2517-2529

2018

Volltextzugriff (PDF)

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

International journal of infectious diseases, 2022-10, Vol.123, p.97-103

2022

Volltextzugriff (PDF)

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

Orphanet journal of rare diseases, 2019-10, Vol.14 (1), p.230-11, Article 230

2019

Volltextzugriff (PDF)

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Breast (Edinburgh), 2024-08, Vol.76, p.103761, Article 103761

2024

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(179)
Mit Volltextzugriff
(171)

Publikationsform

Artikel
(182)
Webseiten
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(97)
Humans
(82)
Female
(78)
Oncology
(77)
Breast Neoplasms - Drug Therapy
(54)
Breast Cancer
(50)
Middle Aged
(48)
Aged
(44)
Tumors
(39)
Adult
(38)
Breast Neoplasms - Pathology
(36)
Chemotherapy
(25)
Treatment Outcome
(25)
Aged, 80 And Over
(23)
Patients
(23)
Erbb-2 Protein
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Cancer Therapies
(21)
Metastasis
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(31)
Cancer Research
(27)
Clinical Cancer Research
(12)
Breast
(6)
Cancer
(6)
Cancers
(6)
The Lancet Oncology
(6)
Breast Cancer Research And Treatment
(5)
Npj Breast Cancer
(4)
Archivos De Bronconeumología
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Top advances of the year: Breast cancer

Enhancing global access to cancer medicines

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

CDK4/6 inhibitors in breast cancer: spotting the difference

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

Nobody dares stopping clinical research, not even COVID-19

Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

Anti-Anisakis antibodies in colon cancer patients and their relationship with γδ T-cells

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

The role of CDK4/6 inhibitors in early breast cancer

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Differences in circulating γδ T cells in patients with primary colon cancer and relation with prognostic factors

ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Suchergebnisse filtern